Previous close | 0.2200 |
Open | 0.2300 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.2100 - 0.2300 |
52-week range | 0.0590 - 0.5350 |
Volume | |
Avg. volume | 746,435 |
Market cap | N/A |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0060 |
Earnings date | 28 July 2024 - 01 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy. Rates of disease progression in patients with Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58% for Cohort 2, when compared to an external cont
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
PharmAust ( ASX:PAA ) Full Year 2023 Results Key Financial Results Revenue: AU$3.90m (down 14% from FY 2022). Net loss...